


Characteristic & Number (\%) of evaluations, N=196 & Count of unique studies, N=57\\
\hline
Type of comparison &  & \\
\hline
\hspace{1em}PCV7 vs NoVax & 24 (12\%) & 14\\
\hline
\hspace{1em}PCV10 vs NoVax & 74 (38\%) & 30\\
\hline
\hspace{1em}PCV13 vs NoVax & 61 (31\%) & 28\\
\hline
\hspace{1em}PCV13 vs PCV10 & 27 (14\%) & 19\\
\hline
\hspace{1em}Others & 10 (5\%) & 6\\
\hline
Number of doses &  & \\
\hline
\hspace{1em}Four & 74 (38\%) & 21\\
\hline
\hspace{1em}Three & 103 (53\%) & 35\\
\hline
\hspace{1em}One/two & 10 (5\%) & 4\\
\hline
\hspace{1em}Unknown & 9 (5\%) & 2\\
\hline
Study perspective &  & \\
\hline
\hspace{1em}Healthcare/payer & 106 (54\%) & 42\\
\hline
\hspace{1em}Societal & 90 (46\%) & 29\\
\hline
Income group &  & \\
\hline
\hspace{1em}Low & 18 (9\%) & 6\\
\hline
\hspace{1em}Lower-middle & 34 (17\%) & 15\\
\hline
\hspace{1em}Upper-middle & 144 (73\%) & 39\\
\hline
Included herd effects & 62 (32\%) & 25\\
\hline
Included serotype replacement & 29 (15\%) & 13\\
\hline
Pneumonia efficacy endpoint & 196 (100\%) & 57\\
\hline
IPD efficacy endpoint & 192 (98\%) & 55\\
\hline
Otitis media efficacy endpoint & 164 (84\%) & 48\\
\hline
Included budget impact analysis & 50 (26\%) & 12\\
\hline
Study decision &  & \\
\hline
\hspace{1em}Cost-saving & 20 (10\%) & 12\\
\hline
\hspace{1em}Cost-effective & 150 (77\%) & 46\\
\hline
\hspace{1em}Not cost-effective & 26 (13\%) & 13\\
\hline

